Skip to main content

Share story

Infrastructure Products

Arm joins European chip-design platform as its first commercial IP provider

Arm joins European chip-design platform as its first commercial IP provider Image: Primary
Arm has signed a strategic framework agreement to become the first commercial intellectual-property provider in the European Chips Design Platform, a European Chips Act initiative funded by the Chips Joint Undertaking. Arm says participating startups, smaller companies and research teams will gain a route to its processor designs, software, development tools and training through its Flexible Access programs. EuroCDP will pair that access with engineering teams that can support system-on-chip development. Eligibility still governs the no-fee startup program, while complimentary academic access is limited to non-commercial research and education.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Arm Newsroom and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...